Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 141

1.

E47 Governs the MYC-CDKN1B/p27KIP1-RB Network to Growth Arrest PDA Cells Independent of CDKN2A/p16INK4A and Wild-Type p53.

Scully KM, Lahmy R, Signaevskaia L, Sasik R, Medal R, Kim H, French R, James B, Wu Y, Lowy AM, Itkin-Ansari P.

Cell Mol Gastroenterol Hepatol. 2018 May 16;6(2):181-198. doi: 10.1016/j.jcmgh.2018.05.002. eCollection 2018.

2.

Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.

Baumgartner JM, Raymond VM, Lanman RB, Tran L, Kelly KJ, Lowy AM, Kurzrock R.

Ann Surg Oncol. 2018 Aug;25(8):2400-2408. doi: 10.1245/s10434-018-6561-z. Epub 2018 Jun 14.

3.

GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets.

Insel PA, Sriram K, Wiley SZ, Wilderman A, Katakia T, McCann T, Yokouchi H, Zhang L, Corriden R, Liu D, Feigin ME, French RP, Lowy AM, Murray F.

Front Pharmacol. 2018 May 22;9:431. doi: 10.3389/fphar.2018.00431. eCollection 2018.

4.

Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients.

Weiss A, Ward EP, Baumgartner JM, Lowy AM, Kelly KJ.

World J Surg Oncol. 2018 Apr 26;16(1):87. doi: 10.1186/s12957-018-1389-3.

5.

Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC.

Reghunathan M, Kelly KJ, Valasek MA, Lowy AM, Baumgartner JM.

Ann Surg Oncol. 2018 Mar;25(3):702-708. doi: 10.1245/s10434-017-6310-8. Epub 2017 Dec 27.

PMID:
29282599
6.

Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery.

Baumgartner JM, McKenzie S, Block S, Costantini TW, Lowy AM.

J Surg Res. 2018 Jan;221:183-189. doi: 10.1016/j.jss.2017.08.053. Epub 2017 Sep 25.

PMID:
29229126
7.

Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy.

Saison-Ridinger M, DelGiorno KE, Zhang T, Kraus A, French R, Jaquish D, Tsui C, Erikson G, Spike BT, Shokhirev MN, Liddle C, Yu RT, Downes M, Evans RM, Saghatelian A, Lowy AM, Wahl GM.

PLoS One. 2017 Dec 6;12(12):e0189051. doi: 10.1371/journal.pone.0189051. eCollection 2017.

8.

Clinical Management: Resectable Disease.

White RR, Lowy AM.

Cancer J. 2017 Nov/Dec;23(6):343-349. doi: 10.1097/PPO.0000000000000291. Review.

PMID:
29189330
9.

GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells.

Wiley SZ, Sriram K, Liang W, Chang SE, French R, McCann T, Sicklick J, Nishihara H, Lowy AM, Insel PA.

FASEB J. 2018 Mar;32(3):1170-1183. doi: 10.1096/fj.201700834R. Epub 2018 Jan 3.

PMID:
29092903
10.

Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.

Kelly KJ, Cajas L, Baumgartner JM, Lowy AM.

Ann Surg Oncol. 2018 Jan;25(1):91-97. doi: 10.1245/s10434-017-6108-8. Epub 2017 Oct 31.

PMID:
29090402
11.

An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).

Berlin JD, Feng Y, Catalano P, Abbruzzese JL, Philip PA, McWilliams RR, Lowy AM, Benson AB III, Blackstock AW.

Oncology. 2018;94(1):39-46. doi: 10.1159/000480295. Epub 2017 Oct 18.

12.

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S.

J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.

PMID:
28784865
13.

Molecular Pathways: Targeting the Microenvironment of Liver Metastases.

Milette S, Sicklick JK, Lowy AM, Brodt P.

Clin Cancer Res. 2017 Nov 1;23(21):6390-6399. doi: 10.1158/1078-0432.CCR-15-1636. Epub 2017 Jun 14. Review.

14.

Overinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care.

Valasek MA, Thung I, Gollapalle E, Hodkoff AA, Kelly KJ, Baumgartner JM, Vavinskaya V, Lin GY, Tipps AP, Hosseini MV, Lowy AM.

PLoS One. 2017 Jun 7;12(6):e0179216. doi: 10.1371/journal.pone.0179216. eCollection 2017.

15.

Hyaluronan-binding peptide for targeting peritoneal carcinomatosis.

Ikemoto H, Lingasamy P, Anton Willmore AM, Hunt H, Kurm K, Tammik O, Scodeller P, Simón-Gracia L, Kotamraju VR, Lowy AM, Sugahara KN, Teesalu T.

Tumour Biol. 2017 May;39(5):1010428317701628. doi: 10.1177/1010428317701628.

16.

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.

Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS.

JAMA Oncol. 2017 Apr 1;3(4):516-522. doi: 10.1001/jamaoncol.2016.5383.

17.

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.

Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, Straughn JM Jr, Dobelbower MC, Lowy AM.

Am J Clin Oncol. 2018 Jul;41(7):716-721. doi: 10.1097/COC.0000000000000353.

18.

Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics.

Chakedis J, French R, Babicky M, Jaquish D, Mose E, Cheng P, Holman P, Howard H, Miyamoto J, Porras P, Walterscheid Z, Schultz-Fademrecht C, Esdar C, Schadt O, Eickhoff J, Lowy AM.

Oncotarget. 2016 Jul 19;7(29):45959-45975. doi: 10.18632/oncotarget.10009.

19.

Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.

Fox RG, Lytle NK, Jaquish DV, Park FD, Ito T, Bajaj J, Koechlein CS, Zimdahl B, Yano M, Kopp J, Kritzik M, Sicklick J, Sander M, Grandgenett PM, Hollingsworth MA, Shibata S, Pizzo D, Valasek M, Sasik R, Scadeng M, Okano H, Kim Y, MacLeod AR, Lowy AM, Reya T.

Nature. 2016 Jun 16;534(7607):407-411. doi: 10.1038/nature17988. Epub 2016 Jun 6.

20.

Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP.

JAMA Surg. 2016 Aug 17;151(8):e161137. doi: 10.1001/jamasurg.2016.1137. Epub 2016 Aug 17.

Supplemental Content

Loading ...
Support Center